Tyvaso

yellow light street light traffic pause slow delay

Pharma

FDA balks at standard nod to Liquidia's PAH rival to United med

The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia in FDA limbo until 2025.

Zoey Becker Aug 19, 2024 11:34am

Courts clear FDA to approve Liquidia's PAH drug Yutrepia

Apr 2, 2024 9:33am

FDA faces lawsuit from United on its Liquidia review process

Feb 21, 2024 2:31pm

United Therapeutics lands blow in inhaled drug patent dispute

Sep 1, 2022 12:17pm

United scores hard-earned FDA approval for inhaled Tyvaso

May 24, 2022 9:38am

Lung safety review delays FDA decision on United's Tyvaso DPI

Mar 1, 2022 10:01am